Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin®)

BioDrugs

Volumn 28, Issue 5, 2014, Pages 451-459

  Hurst, Susan ^a   Ryan, Anne M ^a   Ng, Chee Keng ^a   McNally, James M ^a   Lorello, Leslie G ^a   Finch, Gregory L ^a   Leach, Michael W ^a   Ploch, Stephen A ^b   Fohey, Josh A ^b   Smolarek, Teresa A ^a  

^a PFIZER INC   (United States)

^b Late Stage Developmental Services Covance Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH INHIBITOR; MONOCLONAL ANTIBODY; PF-05280014; TRASTUZUMAB;

ANIMAL; AREA UNDER THE CURVE; COMPARATIVE STUDY; DOSE RESPONSE; EUROPEAN UNION; HALF LIFE TIME; MALE; MOUSE; PEPTIDE MAPPING; TUMOR CELL LINE; UNITED STATES;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; AREA UNDER CURVE; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPEAN UNION; GROWTH INHIBITORS; HALF-LIFE; MALE; MICE; PEPTIDE MAPPING; UNITED STATES;

EID: 84930740273     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-014-0103-4     Document Type: Article

References (23)

1. Hudis CA. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39-51.
2. ®[trastuzumab]: US prescription information. San Francisco, CA, USA: Genentech Inc.; 2010.
3. European Medicines Agency. Herceptin: Authorisation. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000278/human-med-000818.jsp&mid=WC0b01ac058001d124. Accessed 30 Aug 2013.
4. Baselga J, Albanell J, Molina MA, Arribas J. Mechanism of action of trastuzumab and scientific update. Semin Oncol. 2001;28(5 Suppl 16):4-11.
5. Committee for Medicinal Products for Human Use (CHMP). Guideline on Similar Biological Medicinal Products. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003517.pdf. Accessed 11 Mar 2014.
6. Food and Drug Administration. Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. U.S. Department of Health and Human Services. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Accessed 1 Mar 2014.
7. WHO Expert Committee on Biological Standardization. Guidelines on evaluation of Similar Biotherapeutic Products (SBPs). 2010. Available from: http://www.who.int/biologicals/areas/biological-therapeutics/BIOTHERAPEUTICS-FOR-WEB-22APRIL2010.pdf. Accessed 1 Mar 2014.
8. Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products containing monoclonal antibodies - non-clinical and clinical issues. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/06/WC500128686.pdf. Accessed 11 Mar 2014.
9. Kozlowski S, Woodcock J, Midthun K, Sherman RB. Developing the nation's biosimilars program. N Engl J Med. 2011;365(5):385-8.
10. McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther. 2012;91(3):405-17.
11. Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov. 2012;11(7):527-40.
12. Federici M, Lubiniecki A, Manikwar P, Volkin DB. Analytical lessons learned from selected therapeutic protein drug comparability studies. Biologicals. 2013;41(3):131-47.
13. Pegram MD, Konecny G, Slamon DJ. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res. 2000;103:57-75.
14. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 1999;18(13):2241-51.
15. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 1998;58(13):2825-31.
16. European Medicines Agency. Herceptin: EPAR Scientific Discussion. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific-Discussion/human/000278/WC500049816.pdf. Accessed 22 Aug 2013.
17. Wang W, Prueksaritanont T. Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited. Biopharm Drug Dispos. 2010;31(4):253-63.
18. Crouch SP, Kozlowski R, Slater KJ, Fletcher J. The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. J Immunol Methods. 1993;160(1):81-8.
19. Houk TW Jr, Ue K. The measurement of actin concentration in solution: a comparison of methods. Anal Biochem. 1974;62(1):66-74.
20. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, Inc.; 1982.
21. Genentech Inc. Herceptin Product Monograph. Health Canada. Available from: http://webprod3.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=64277. Accessed 27 Mar 2012.
22. Brinks V, Jiskoot W, Schellekens H. Immunogenicity of therapeutic proteins: the use of animal models. Pharm Res. 2011;28(10):2379-85.
23. Bugelski PJ, Treacy G. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. Curr Opin Mol Ther. 2004;6(1):10-6.